Dual targeting of CDK4/6 and BCL2 pathways augments tumor response in estrogen receptor-positive breast cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 53 of the 55 references it cites were found in a registry or an index.
Abstract
Abstract Purpose: Although cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors significantly extend tumor response in patients with metastatic estrogen receptor–positive (ER+) breast cancer, relapse is almost inevitable. This may, in part, reflect the failure of CDK4/6 inhibitors to induce apoptotic cell death. We therefore evaluated combination therapy with ABT-199 (venetoclax), a potent and selective BCL2 inhibitor. Experimental Design: BCL2 family member expression was assessed following treatment with endocrine therapy and the CDK4/6 inhibitor palbociclib. Functional assays were used to determine the impact of adding ABT-199 to fulvestrant and palbociclib in ER+ breast cancer cell lines, patient-derived organoid (PDO), and patient-derived xenograft (PDX) models. A syngeneic ER+ mouse mammary tumor model was used to study the effect of combination therapy on the immune system. Results: Triple therapy was well tolerated and produced a superior and more durable tumor response compared with single or doublet therapy. This was associated with marked apoptosis, including of senescent cells, indicative of senolysis. Unexpectedly, ABT-199 resulted in Rb dephosphorylation and reduced G1–S cyclins, most notably at high doses, thereby intensifying the fulvestrant/palbociclib–induced cell-cycle arrest. Interestingly, a CRISPR/Cas9 screen suggested that ABT-199 could mitigate loss of Rb (and potentially other mechanisms of acquired resistance) to palbociclib. ABT-199 did not abrogate the favorable immunomodulatory effects of palbociclib in a syngeneic ER+ mammary tumor model and extended tumor response when combined with anti-PD1 therapy. Conclusions: This study illustrates the potential for targeting BCL2 in combination with CDK4/6 inhibitors and supports investigation of combination therapy in ER+ breast cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA, best known as PI3K a ) and BCL2 apoptosis regulator (BCL2) blockers boost the ability of CDK4/CDK6 inhibitors to promote antigen presentation (as well as PD-L1 expression) in models of breast cancer”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Whittle et al., 2020
In the citing paper
“correlating with (1) superior disease control in vivo , along with the systemic depletion of immunosuppressive cells including TREG cells and myeloidderived suppressor cells (MDSCs), as well as (2) added therapeutic benefits from ICIs”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Whittle et al., 2020
In the citing paper
“In line with such a ''senolytic'' activity, venetoclax effectively eliminates HR + breast cancer cells undergoing senescence in response to CDK4/CDK6 inhibitors, culminating in increased levels of both MHC class I molecules and PD-L1 (Whittle et al., 2020).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Whittle et al., 2020
Citations
Cites
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058 · cited 1×
“Venetoclax (ABT-199/ GDC-0199), a potent and highly selective inhibitor of BCL2 (20), has demonstrated single-agent activity in chronic lymphocytic leukemia (21) and in combination therapy for a number of hematologic malignancies (18).”
BackgroundPalbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
A living biobank of breast cancer organoids captures disease heterogeneity
Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F., Balgobind, A. V., Wind, K., Gracanin, A., Begthel, H., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.010 · Cited by 1,973 · cited 4×
“For PDXorganoids, single-cell suspensions were prepared from PDX tumors, then sorted by flow cytometry and plated in organoidmediumoptimized for breast tumors (24, 25).”
BackgroundMethodInfluentialSelf-citationTargeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,900 · cited 1×
“Venetoclax (ABT-199/ GDC-0199), a potent and highly selective inhibitor of BCL2 (20), has demonstrated single-agent activity in chronic lymphocytic leukemia (21) and in combination therapy for a number of hematologic malignancies (18).”
BackgroundMONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
Letai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., & Korsmeyer, S. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00127-7 · Cited by 1,677 · cited 1×
“ABT-199 alone (or in combination) increased expression of pro-apoptotic BIM, ameasure of primed cells (28) and induced cleaved PARP and cleaved caspase-3 (CC3; Fig.”
BackgroundCDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513 · cited 9×
“CDK4/6 inhibitors elicit a senescence phenotype (7, 8) that can result in cells becomingmore resistant to apoptosis (13, 14).”
BackgroundResultInfluentialFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398 · cited 3×
“The link between estrogen receptor (ER) signaling and G1–S phase cell-cycle progression has informed the combined use of CDK4/6 inhibitors with endocrine therapy (11).”
BackgroundMethodCyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370 · cited 1×
“Introduction Estrogen receptor–positive (ERþ) breast cancers frequently exhibit deregulation of the cyclin-dependent kinase 4 and 6 (CDK4/6)/cyclin D1 (CCND1)/retinoblastoma (Rb) signaling pathway, resulting in uncontrolled cellular proliferation (1, 2).”
BackgroundOverall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Cited by
Targeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
Dekkers, J. F., van Vliet, E. J., Sachs, N., Rosenbluth, J. M., Kopper, O., Rebel, H. G., Wehrens, E. J., Piani, C., Visvader, J. E., Verissimo, C. S., et al. (2021) · Nature Protocols · doi:10.1038/s41596-020-00474-1 · Cited by 272
Self-citationImmunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Zhou, Z., Cong, L., & Cong, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.762184 · Cited by 178
“Breast CSC-derived CDK4/6 and BCL2 signaling pathway inhibitors 3 3 BME (51) Breast CSC-derived Docetaxel, Doxorubicin P4HA inhibitor 3 1 BME (52)”
BackgroundBasu, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107943 · Cited by 171
Metadata
- Authors
- Whittle, J. R., Vaillant, F., Surgenor, E., Policheni, A. N., Giner, G., Capaldo, B. D., Chen, H.-R., Liu, H. K., Dekkers, J. F., Sachs, N., Clevers, H., Fellowes, A., Green, T., Xu, H., Fox, S. B., Herold, M. J., Smyth, G. K., Gray, D. H. D., Visvader, J. E., & Lindeman, G. J.
- Affiliations
- The University of Melbourne (AU)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Royal Netherlands Academy of Arts and Sciences (NL)
- Peter MacCallum Cancer Centre (AU)
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2020-08-01
- Volume
- 26
- Issue
- 15
- Pages
- 4120-4134
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W3015152600
- Cited by
- 102
- References
- 55
- Citations by year
- 2026: 15 · 2025: 10 · 2024: 10 · 2023: 20 · 2022: 21 · 2021: 20 · 2020: 6
- FWCI
- 9.43
- Type
- journal article
- Language
- en
- Open access
- green
- dspace.library.uu.nl
- Licence
- other-oa
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- KNAW research portal (Royal Academy of Art and Sciences (KNAW)) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Funders
- National Health and Medical Research Council (1054618, 1113133, 1153049)
- National Breast Cancer Foundation (NT-13-06, IIRS-19-004)
- Breast Cancer Research Foundation (BCRF-18-182)
- Cancer Australia (1165878)
- Qualtrough Cancer Research Fund Joan Marshall Breast Cancer Research Fund Collie Foundation (2017F001)
- NHMRC (1090236, 1158024, 1058892, 1037230, 1078730, 1175960)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- estrogen receptor-positive breast cancer, CDK4/6 inhibitors, BCL-2 inhibition, venetoclax, palbociclib, fulvestrant, combination therapy, senolysis, Rb dephosphorylation, acquired drug resistance, immunomodulation, anti-PD-1 therapy, patient-derived xenografts, patient-derived organoids
- MeSH terms
- Fulvestrant, Adult, Aged, Animals, Antineoplastic Combined Chemotherapy Protocols, Breast, Breast Neoplasms, Disease Models, Animal, Female, Humans, Mastectomy, Middle Aged, Organoids, Piperazines, Pyridines, Receptors, Estrogen, Sulfonamides, Chemotherapy, Adjuvant, Apoptosis, Drug Resistance, Neoplasm, Bridged Bicyclo Compounds, Heterocyclic, Proto-Oncogene Proteins c-bcl-2, Neoadjuvant Therapy, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dual targeting of CDK4/6 and BCL2 pathways augments tumor response in estrogen receptor-positive breast cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-1872
- The paper
- Whittle, J. R., Vaillant, F., Surgenor, E., Policheni, A. N., Giner, G., Capaldo, B. D., Chen, H.-R., Liu, H. K., Dekkers, J. F., Sachs, N., Clevers, H., Fellowes, A., Green, T., Xu, H., Fox, S. B., Herold, M. J., Smyth, G. K., Gray, D. H. D., Visvader, J. E., & Lindeman, G. J. (2020). Dual targeting of CDK4/6 and BCL2 pathways augments tumor response in estrogen receptor-positive breast cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-1872
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.